Defilade Capital Management, L.P.: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 2088557) · Explore on the interactive board
Defilade Capital Management, L.P. disclosed 39 US equity positions worth $746.9m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is LLY at 6.3% of the reported book, followed by PFE, VEEV. The top ten holdings are 46.5% of the book, and the portfolio behaves like about 29 equal-weight positions. Versus the prior filing it opened 20 new positions, added to 7, reduced 10 and exited 12. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Defilade Capital Management, L.P. own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 20 new, 7 added, 10 reduced, 12 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | LLY ELI LILLY & CO | Healthcare | 6.3% | $46.9m | 39,086 | 89% | added |
| 2 | PFE PFIZER INC | Healthcare | 5.7% | $42.7m | 1,771,743 | 21% | added |
| 3 | VEEV VEEVA SYS INC | Healthcare | 5.6% | $42.0m | 236,709 | – | new |
| 4 | BMRN BIOMARIN PHARMACEUTICAL INC | Healthcare | 5.2% | $39.0m | 682,005 | – | new |
| 5 | PTCT PTC THERAPEUTICS INC | Healthcare | 4.7% | $35.4m | 433,699 | 15% | added |
| 6 | BAX BAXTER INTL INC | Healthcare | 4.2% | $31.1m | 1,459,380 | – | new |
| 7 | INSM INSMED INC | Healthcare | 4.0% | $30.0m | 281,838 | 45% | added |
| 8 | ZBH ZIMMER BIOMET HOLDINGS INC | Healthcare | 3.7% | $27.3m | 317,426 | -45% | reduced |
| 9 | PODD INSULET CORP | Healthcare | 3.6% | $26.9m | 176,932 | – | new |
| 10 | TMO THERMO FISHER SCIENTIFIC INC | Healthcare | 3.5% | $26.0m | 51,934 | – | new |
| 11 | ABT ABBOTT LABORATORIES | Healthcare | 3.5% | $25.9m | 285,778 | – | new |
| 12 | ASND ASCENDIS PHARMA A/S | Healthcare | 3.4% | $25.3m | 94,843 | – | new |
| 13 | SOLV SOLVENTUM CORP | Healthcare | 3.3% | $24.4m | 316,454 | – | new |
| 14 | MDT MEDTRONIC PLC | Healthcare | 3.2% | $23.7m | 303,301 | – | new |
| 15 | ELAN ELANCO ANIMAL HEALTH INC | Healthcare | 2.8% | $21.3m | 864,080 | -7% | reduced |
| 16 | AGIO AGIOS PHARMACEUTICALS INC | Healthcare | 2.7% | $20.3m | 546,848 | – | new |
| 17 | NVST ENVISTA HOLDINGS CORPORATION | Healthcare | 2.6% | $19.1m | 726,108 | – | new |
| 18 | RVMD REVOLUTION MEDICINES INC | Healthcare | 2.1% | $15.5m | 82,827 | -74% | reduced |
| 19 | ICUI ICU MED INC | Healthcare | 2.1% | $15.5m | 105,700 | -58% | reduced |
| 20 | COGT COGENT BIOSCIENCES INC | Healthcare | 2.0% | $15.2m | 393,441 | 12% | added |
| 21 | LNTH LANTHEUS HLDGS INC | Healthcare | 2.0% | $14.7m | 132,662 | -47% | reduced |
| 22 | OCUL OCULAR THERAPEUTIX INC | Healthcare | 2.0% | $14.6m | 1,490,286 | 0% | held |
| 23 | ELDN ELEDON PHARMACEUTICALS INC | 1.9% | $13.9m | 3,525,338 | -1% | reduced | |
| 24 | TYRA TYRA BIOSCIENCES INC | Healthcare | 1.6% | $12.0m | 376,870 | – | new |
| 25 | OLMA OLEMA PHARMACEUTICALS INC | Healthcare | 1.5% | $11.6m | 924,758 | -39% | reduced |
| 26 | ORIC ORIC PHARMACEUTICALS INC | Healthcare | 1.5% | $11.3m | 1,047,690 | 24% | added |
| 27 | LRMR LARIMAR THERAPEUTICS INC | Healthcare | 1.5% | $11.2m | 3,670,135 | – | new |
| 28 | GMED GLOBUS MED INC | Healthcare | 1.5% | $11.0m | 139,637 | -61% | reduced |
| 29 | ENOV ENOVIS CORPORATION | Healthcare | 1.5% | $11.0m | 531,945 | – | new |
| 30 | EVMN EVOMMUNE INC | 1.4% | $10.5m | 793,145 | 17% | added | |
| 31 | TFX TELEFLEX INCORPORATED | Healthcare | 1.4% | $10.2m | 80,118 | – | new |
| 32 | DNLI DENALI THERAPEUTICS INC | Healthcare | 1.3% | $10.1m | 391,866 | -71% | reduced |
| 33 | GKOS GLAUKOS CORP | Healthcare | 1.2% | $9.3m | 66,519 | – | new |
| 34 | STAA STAAR SURGICAL CO | Healthcare | 1.2% | $9.2m | 322,126 | – | new |
| 35 | PACS PACS GROUP INC | Healthcare | 1.2% | $9.2m | 215,675 | -64% | reduced |
| 36 | CRNXGBP CRINETICS PHARMACEUTICALS IN | 1.2% | $9.0m | 239,440 | – | new | |
| 37 | LIVN LIVANOVA PLC | Healthcare | 1.2% | $8.8m | 107,373 | – | new |
| 38 | BDTX BLACK DIAMOND THERAPEUTICS I | 0.4% | $3.1m | 1,674,999 | – | new | |
| 39 | MREO MEREO BIOPHARMA GROUP PLC | Healthcare | 0.3% | $2.4m | 7,558,756 | 0% | held |
What did Defilade Capital Management, L.P. sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| HSIC SCHEIN HENRY INC | 16.8% | $46.0m |
| BDX BECTON DICKINSON & CO | 16.1% | $43.9m |
| DXCM DEXCOM INC | 12.4% | $33.8m |
| ISRG INTUITIVE SURGICAL INC | 11.4% | $31.2m |
| NBIX NEUROCRINE BIOSCIENCES INC | 10.1% | $27.7m |
| ITGR INTEGER HLDGS CORP | 6.9% | $18.7m |
| BIIB BIOGEN INC | 6.5% | $17.7m |
| TNDM TANDEM DIABETES CARE INC | 5.4% | $14.6m |
| NUVALENT INC | 4.9% | $13.3m |
| ASND ASCENDIS PHARMA A/S | 4.3% | $11.9m |
| ALGN ALIGN TECHNOLOGY INC | 4.2% | $11.5m |
| BHVN BIOHAVEN LTD | 1.0% | $2.7m |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 95.1% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Defilade Capital Management, L.P.'s portfolio?
Across every quarter Defilade Capital Management, L.P. has filed, its median largest position is 6.8% of the book and its median top-ten weight is 49.5%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 11.0 completed holding spells, the median lasted 1.0 quarters; 39.0 positions are still open and their final length is unknown.